Prescription attached:-
TC(1494)*.(01). Cardiology Department Case No (51)* — COPD and Hypertension with Possible IHD (Reported LVEF ~50–55%); Seven-Drug Prescription Review | English + বাংলা
Author / লেখক: Md.Rafiqul Islam Lipu | LIPU MED | Review date: Tuesday, 03 November 2026 | Prescription dated 17 July 2026. Department: Cardiology, with pulmonary co-morbidity. Patient identity withheld in this public version.
Website verification (03 Nov 2026): The public Medical Blog category displayed 1,492 posts; Cardiology displayed 50 posts (latest clearly numbered Case 50). This report is provisionally labelled TC(1494) to avoid collision with a separately prepared unpublished TC(1493) draft; the website itself does NOT verify 1494 as assigned or published. Cardiology Case 51 is proposed, not reserved. Recheck archives and prior drafts immediately before publishing. Medical Blog category; Cardiology archive.
Evidence key: [D] = directly documented in image; [U] = handwriting uncertain; [I] = inference, not a physician diagnosis; [V] = independently verified brand identity. Clinical confidence scores describe interpretation reliability, not diagnostic probabilities from a validated model.
Safety alert: Efodio is domperidone 10 mg, not a vitamin or antihistamine. In a ~60-year-old with queried ischaemic heart disease, the drug needs cardiac/QT and interaction review. The prescription alone does not show an ECG or electrolyte result. Also verify apparently twice-daily Lanso D (dexlansoprazole) and all indistinct duration/volume instructions before treatment.
01. Patient and Doctor — Original Prescription Details / রোগী ও চিকিৎসকের তথ্য
| Field / বিষয় | Verbatim / interpretation | Evidence / Confidence |
|---|---|---|
| Visit date | 17 July 2026 | [D] 1.00 |
| Patient | Adult male; age appears 60 years; name redacted publicly | [D] 0.94 age; privacy preserved |
| Prescriber | Dr. A. F. M. Arifur Rahman, Cardiology/Medicine (printed letterhead); BMDC number printed; not independently license-verified | [D] 0.97 |
| Recorded C/H | COPD; HTN; “?IHD (EF=50–55%)” appears handwritten | [D/U] 0.92 for COPD/HTN, 0.78 for queried IHD, 0.82 for EF |
| Vitals | BP 130/90 mmHg, pulse probably 86/min | [D/U] BP 0.96; pulse 0.75 |
| Exam | Heart S1+S2+0 and lungs “clear” appear written | [D/U] 0.85 |
| Investigation results | No ECG tracing, dated echocardiography report, spirometry values or blood results attached | [D] 0.98 |
| Reported EF | Handwritten EF≈50–55% is a reported note, not independently confirmed ECHO result | [U] 0.82 |
02. Definition, Etiology & Pathophysiology / সংজ্ঞা, কারণ ও রোগপ্রক্রিয়া
Hypertension / উচ্চ রক্তচাপ: chronic elevated arterial pressure requiring measurement across properly obtained readings; office BP 130/90 is one snapshot, not a diagnostic staging basis alone. Genetic, renal, vascular and lifestyle mechanisms contribute. Confidence: 0.98 (known history, not pathogenesis in this individual).
COPD / দীর্ঘস্থায়ী অবস্ট্রাকটিভ পালমোনারি রোগ: persistent airflow obstruction, commonly associated with tobacco or biomass exposure and airway/parenchymal injury; diagnosis requires post-bronchodilator FEV1/FVC <0.70 in compatible context, per GOLD 2026. This note says COPD but no spirometry is present. Confidence: 0.98 as documented history; 0.54 as independently confirmed physiology.
Possible IHD / সম্ভাব্য ইস্কেমিক হৃদ্রোগ: myocardial oxygen supply–demand imbalance often caused by coronary atherosclerosis. A handwritten question mark before IHD means suspected, not confirmed. EF ~50–55%, if accurate, does not prove or exclude coronary disease or heart failure. Confidence: 0.84 for suspected wording; 0.30 for confirmed IHD (not claimed).
Possible GERD and constipation: acid reflux occurs when gastric contents reach oesophagus; gastric acid suppression/alginate are compatible with symptoms. Reduced colonic motility may cause constipation, for which sodium picosulfate could be prescribed. Neither symptom is a documented chief complaint here. Confidence: 0.58, 0.56 (inferences only).
03. Prescription-Documented 20-Section Audit / প্রেসক্রিপশন-নথিভুক্ত ২০টি বিভাগ
1. C/C — Chief Complaint
Not separately documented. The column is marked C/H, not a direct report of cough, dyspnoea, chest pain or heartburn. / প্রধান উপসর্গ আলাদা করে লেখা নেই. Confidence / নির্ভরযোগ্যতা: 0.99.
2. O/E — On Examination
BP ~130/90, pulse ~86/min; lungs clear; heart note appears S1+S2+0. Other printed boxes not reliably marked. / রক্তচাপ ১৩০/৯০, পালস সম্ভবত ৮৬। Confidence / নির্ভরযোগ্যতা: 0.85.
3. I/H — Immunization History
Not documented; vaccination record (influenza, pneumococcal etc.) should be asked for COPD. / টিকা ইতিহাস নেই। Confidence / নির্ভরযোগ্যতা: 0.99.
4. O/H — Occupational History
Not documented; ask about biomass smoke, dust, fumes, and job exposures. / পেশাগত ইতিহাস নেই। Confidence / নির্ভরযোগ্যতা: 0.99.
5. D/H — Drug History
Present seven drugs only; previous medicines, antiplatelets, statins, inhalers and allergies unknown. / পূর্বের ওষুধের ইতিহাস নেই। Confidence / নির্ভরযোগ্যতা: 0.99.
6. M/H — Medical History
C/H includes COPD, HTN, ?IHD, handwritten EF ~50–55%. Diabetes, MI, PCI, HF, CKD unrecorded. / COPD-HTN লেখা, IHD সন্দেহ। Confidence / নির্ভরযোগ্যতা: 0.90.
7. O/S/E — Other Systemic Examination
No reliable detailed systemic findings; the printed anaemia, jaundice, oedema, cyanosis boxes are not readable as definite positives/negatives. / অন্যান্য সিস্টেমের পরীক্ষা স্পষ্ট নয়। Confidence / নির্ভরযোগ্যতা: 0.95.
8. Plan — Treatment Plan
Seven medicines written; no clearly legible diagnostic plan. / সাতটি ওষুধ, কিন্তু বিশদ পরিকল্পনা নেই। Confidence / নির্ভরযোগ্যতা: 0.97.
9. O/G/E — Obstetric/Gynecological Examination
Not applicable (male patient). / পুরুষ রোগীর ক্ষেত্রে প্রযোজ্য নয়। Confidence / নির্ভরযোগ্যতা: 1.00.
10. Advice — Doctor Instructions
Meal-timing checkboxes marked for medications; duration and some handwritten instructions are unclear. Printed smoking and follow-up advice cannot be assumed personally instructed. / খাবারের আগে-পরে চিহ্ন আছে; মেয়াদ অস্পষ্ট। Confidence / নির্ভরযোগ্যতা: 0.84.
11. Doctor Dx — Written Diagnosis
No explicit “Dx:” entry; history C/H records COPD, HTN, and ?IHD, not confirmed final diagnoses of additional symptoms. / আলাদা ডায়াগনোসিস নেই। Confidence / নির্ভরযোগ্যতা: 0.95.
12. Investigations
ECG/ECHO/spirometry/metabolic labs not documented with results; printed template checklists are not orders by themselves. / রিপোর্ট সংযুক্ত নেই। Confidence / নির্ভরযোগ্যতা: 0.98.
13. Drugs
Abecab, Brezofil, Monocast, Lanso D, Efodio, Progavi, Abdolax. Items 5 and 6 confirmed by user. / মোট সাতটি। Confidence / নির্ভরযোগ্যতা: 0.98.
14. Reviewer Working Dx
Treated hypertension and documented COPD; possible coronary disease; suspected reflux/dyspepsia and constipation; possible coexisting asthma/rhinitis. / সম্ভাব্য রোগ, নিশ্চিত নয়। Confidence / নির্ভরযোগ্যতা: 0.80.
15. Medication–Disease Links
Abecab→HTN, Brezofil→obstructive-airway symptoms, Monocast→asthma/rhinitis possibility; Lanso D/Efodio/Progavi→GI symptoms, Abdolax→constipation. / ওষুধ রোগের ইঙ্গিত, প্রমাণ নয়। Confidence / নির্ভরযোগ্যতা: 0.91.
16. Explicit Histories — red highlight
COPD; HTN; ?IHD (EF≈50–55%). / লাল অংশে কেবল লিখিত ইতিহাস। Confidence / নির্ভরযোগ্যতা: 0.88.
17. Doctor vs Reviewer
Physician recorded a history; reviewer highlights drug safety and missing clinical evidence. / চিকিৎসকের নোট বনাম সতর্ক বিশ্লেষণ। Confidence / নির্ভরযোগ্যতা: 0.95.
18. Bangla Diagnosis
নথিভুক্ত COPD ও উচ্চ রক্তচাপ; সম্ভাব্য IHD; ওষুধ দেখে GERD, বমিভাব/ডিসপেপসিয়া ও কোষ্ঠকাঠিন্যের সম্ভাবনা, নিশ্চিত নয়। Confidence / নির্ভরযোগ্যতা: 0.84.
19. Diagnostic Confidence
HTN history 0.98; COPD history 0.95; queried IHD 0.75; EF value reading 0.82; inferred GERD 0.58; constipation 0.56. Confidence / নির্ভরযোগ্যতা: 1.00.
20. MedEx Therapeutic Classification
Amlodipine+olmesartan combined antihypertensive; doxophylline bronchodilator; montelukast leukotriene antagonist; dexlansoprazole PPI; domperidone prokinetic; alginate/antacids; sodium picosulfate stimulant laxative. Confidence / নির্ভরযোগ্যতা: 0.98.
04. Physician Clinical Observations / চিকিৎসকের পর্যবেক্ষণ
The note suggests BP 130/90, pulse ~86/min, normal S1/S2 without noted extra sound, and clear lungs on that visit. A clear chest on auscultation does not disprove COPD; auscultation cannot establish COPD severity. The handwritten LVEF ~50–55% may represent a previous ECHO, but no dated report is supplied. The patient was seen 17 July 2026, so clinical status on 03 November 2026 is unknown. / ১৭ জুলাইয়ের শারীরিক পরীক্ষা দিয়ে আজকের অবস্থা নিশ্চিত করা যাবে না. Confidence: 0.92.
05. Clinical Differential Diagnosis / সম্ভাব্য বিকল্প রোগ
| Condition | Supporting clue | Limitation / next discriminating test | Confidence |
|---|---|---|---|
| Established HTN (history) | HTN handwritten; treated with Abecab | Serial standardized office/home BP, kidney/electrolyte assessment | 0.98 history |
| COPD | COPD handwritten; doxophylline | Post-bronchodilator spirometry mandatory for objective confirmation | 0.95 history; 0.55 confirmed |
| Asthma or COPD–asthma coexistence | Montelukast, bronchodilator | Variability, reversibility, eosinophils, history; not implied from montelukast alone | 0.46 |
| Chronic coronary syndrome / CAD | ?IHD in C/H; cardiovascular risk | Symptoms, ECG, ECHO, clinician-guided CAD testing; no chest pain documented | 0.55 |
| GERD/functional dyspepsia | PPI + alginate + domperidone | Ask heartburn, regurgitation, dysphagia, melena, weight loss | 0.58 |
| Functional/drug-associated constipation | Sodium picosulfate prescription | Stool frequency/form, medication and alarm history | 0.56 |
| Heart failure | Possible cardiac comorbidity only | No signs, BNP, report, symptoms; EF 50–55% alone insufficient | 0.25 — not diagnosed |
06. Doctor’s Written Dx vs LIPU MED Working Dx / চিকিৎসকের রোগনির্ণয় বনাম পর্যালোচনা
| Comparison | Physician-documented | Reviewer interpretation |
|---|---|---|
| Shared / মিল | COPD and HTN in C/H | Recognized COPD/HTN history; do not assert objective COPD confirmation |
| IHD | Written “?IHD” | Keep as possible rather than confirmed coronary disease |
| EF | Approx. “EF=50–55%” in history | Unverified reported LV ejection fraction; cannot classify heart failure without symptoms and echo |
| GI and bowel | No explicit C/C/Dx | GERD/dyspepsia/constipation suggested by drug choices, not confirmed |
| Safety | No readable risk–benefit notes | Domperidone QT risk, COPD guideline mismatch, possible excessive PPI frequency, sodium load review |
Assessment: Differences are about available evidence, not proof the prescriber was wrong. No clinical examination, investigations, list of existing medicines, or reason for this specific dose/duration is available to the reviewer. Confidence: 0.94.
07. Medication List — Original and Drug Safety / মূল সাতটি ওষুধ ও নিরাপত্তা
| # | Written drug / generic confirmed | Prescription reading (not instructions) | MedEx list price | Critical note |
|---|---|---|---|---|
| 1 | Abecab 5/20 — amlodipine+olmesartan | 1–0–0–0; after food | ৳12/tab | BP, K+, creatinine |
| 2 | Brezofil 200 — doxophylline | 0–0–0–1; after food | ৳8/tab | Review rhythm/COPD standard inhalers |
| 3 | Monocast 10 — montelukast | 0–0–0–1; after food | ৳17.50/tab | Neuropsychiatric boxed warning |
| 4 | Lanso D 30 — dexlansoprazole only | Appears 1–0–0–1; before food | ৳10/cap | BID dose needs confirmation; D≠domperidone |
| 5 | Efodio 10 — domperidone | 1–0–0–1; before food | ৳4.50/tab | High-priority QT/cardiac review |
| 6 | Progavi — alginate+bicarbonate+carbonate suspension | “2 চামচ” AM & PM appears; after food; CHECK actual mL | ৳300/200 mL | Sodium load and volume ambiguity |
| 7 | Abdolax 10 — sodium picosulfate | 0–0–0–1 at night; condition unclear | ৳10/tab | PRN versus daily unclear |
Crucial: The dosing entries above are transcription hypotheses from the photographed prescription dated July 2026. This is NOT a new prescription or a recommendation to start, stop, or change these medicines. Where doubtful, obtain direct verification from the prescriber/pharmacist.
08. Seven Medicines — Individual 17-Field MedEx Reviews / প্রতিটি ওষুধের ১৭টি তথ্য
1. Abecab 5 mg + 20 mg — Amlodipine besilate 5 mg + olmesartan medoxomil 20 mg
Manufacturer: ACI / Advanced Chemical Industries PLC. Observed row: 1–0–0–0; after food tick appears marked; treatment duration illegible.. Identification confidence: 0.98.
| Field / ক্ষেত্র | Patient-specific verified information / যাচাইকৃত তথ্য |
|---|---|
| 1. Generic ingredient(s) / জেনেরিক | Amlodipine besilate 5 mg + olmesartan medoxomil 20 mg |
| 2. Brand / ব্র্যান্ড | Abecab |
| 3. Alternate Bangladesh brands / বিকল্প ব্র্যান্ড | Azoren 5/20, Bazoka 5/20, Belsar-M 5/20, Bizoran 5/20 (same actives; no automatic substitution). |
| 4. Therapeutic class / থেরাপিউটিক শ্রেণি | Combined antihypertensive preparations |
| 5. Pharmacological class / ফার্মাকোলজিক শ্রেণি | Dihydropyridine calcium-channel blocker + angiotensin-II AT₁-receptor blocker (ARB) |
| 6. Primary purpose / প্রধান উদ্দেশ্য | Blood-pressure lowering and reduction of long-term cardiovascular risk. |
| 7. Patient-specific reason / এই রোগীতে কেন | HTN documented and office BP 130/90 mmHg; evidence strong for intended antihypertensive role, but single BP cannot indicate overall control. |
| 8. Adverse effects / পার্শ্বপ্রতিক্রিয়া | Ankle oedema, flushing, headache, dizziness, low BP; hyperkalaemia/renal-function change from ARB; rare olmesartan-associated enteropathy. |
| 9. Verified MedEx direct link / মেডএক্স সরাসরি | Open verified brand monograph |
| 10. Price, form, composition / দাম ও গঠন | Tablet; 5 mg + 20 mg; ৳12.00/tablet; ৳168/14-tablet strip (listed); Amlodipine besilate 5 mg + olmesartan medoxomil 20 mg. |
| 11. Mechanism / কার্যপ্রণালি | Amlodipine relaxes arteriolar smooth muscle by inhibiting L-type calcium entry; olmesartan suppresses angiotensin-II-mediated vasoconstriction and aldosterone action. |
| 12. Indications / ব্যবহার | Hypertension; not proof of CAD or heart failure. |
| 13. Interactions and contraindications / মিথষ্ক্রিয়া ও নিষেধাজ্ঞা | Avoid concurrent ACE inhibitor/other ARB/aliskiren without specialist rationale; potassium supplements/NSAIDs can raise renal and K+ risk. Significant pregnancy fetal toxicity (ARB). |
| 14. Precautions / সতর্কতা | Check seated/standing BP, creatinine/eGFR and K+ at baseline and ~2–4 weeks after starting/change; review dehydration and oedema. |
| 15. Dose & administration / ডোজ | Prescription: one tablet each morning. Brand usual 5/20 mg once daily; adjustment requires clinician. |
| 16. Pregnancy & lactation / গর্ভাবস্থা ও স্তন্যদান | Contraindicated in pregnancy because of olmesartan; breastfeeding alternatives preferred under clinical advice. |
| 17. Other preparations & combinations / অন্যান্য ফর্ম | The tablet itself combines amlodipine+olmesartan; other antihypertensive combinations require reconciliation. |
Clinical caution / সতর্কতা: Brand descriptions and typical indications are not evidence that the patient has every listed disease, nor a substitute for the prescribing doctor. Drug-price listings may change. MedEx source.
2. Brezofil 200 mg — Doxophylline 200 mg
Manufacturer: Incepta Pharmaceuticals Ltd.. Observed row: 0–0–0–1; after food marked.. Identification confidence: 0.93.
| Field / ক্ষেত্র | Patient-specific verified information / যাচাইকৃত তথ্য |
|---|---|
| 1. Generic ingredient(s) / জেনেরিক | Doxophylline 200 mg |
| 2. Brand / ব্র্যান্ড | Brezofil |
| 3. Alternate Bangladesh brands / বিকল্প ব্র্যান্ড | Ascova 200 mg, Axofyl 200 mg, Docofin 200 mg; same molecule. Formulation/strength must match. |
| 4. Therapeutic class / থেরাপিউটিক শ্রেণি | Bronchodilator, methylxanthine derivatives |
| 5. Pharmacological class / ফার্মাকোলজিক শ্রেণি | Xanthine derivative / non-inhaled bronchodilator |
| 6. Primary purpose / প্রধান উদ্দেশ্য | Bronchial smooth-muscle relaxation; symptomatic relief of obstructive airway disease. |
| 7. Patient-specific reason / এই রোগীতে কেন | COPD documented; the medication is compatible with bronchodilator treatment but does not confirm spirometry or exacerbation status. |
| 8. Adverse effects / পার্শ্বপ্রতিক্রিয়া | Nausea, abdominal discomfort, headache, insomnia, palpitations/tachycardia, rare arrhythmia. |
| 9. Verified MedEx direct link / মেডএক্স সরাসরি | Open verified brand monograph |
| 10. Price, form, composition / দাম ও গঠন | Tablet; 200 mg; ৳8.00/tablet; ৳80/10-tablet strip; Doxophylline 200 mg. |
| 11. Mechanism / কার্যপ্রণালি | Doxophylline is a xanthine-derived bronchodilator; phosphodiesterase-related smooth-muscle relaxation is proposed, with a pharmacology profile differing from theophylline. |
| 12. Indications / ব্যবহার | Bronchospasm/COPD/asthma symptoms; not an acute rescue inhaler. |
| 13. Interactions and contraindications / মিথষ্ক্রিয়া ও নিষেধাজ্ঞা | Avoid other xanthines; caution with sympathomimetics, caffeine excess and interacting drugs; verify full medication list. |
| 14. Precautions / সতর্কতা | Especially review palpitations, ECG/rhythm, coronary history and age; inhaled long-acting COPD therapy should be reviewed against GOLD recommendations. |
| 15. Dose & administration / ডোজ | Handwriting indicates 200 mg once nightly. Do not increase to package-listed multiple daily doses without prescriber confirmation. |
| 16. Pregnancy & lactation / গর্ভাবস্থা ও স্তন্যদান | Limited safety data; avoid routine use without specialist decision in pregnancy/lactation. |
| 17. Other preparations & combinations / অন্যান্য ফর্ম | No fixed combination in this item; check for concomitant bronchodilator inhalers and duplicate xanthines. |
Clinical caution / সতর্কতা: Brand descriptions and typical indications are not evidence that the patient has every listed disease, nor a substitute for the prescribing doctor. Drug-price listings may change. MedEx source.
3. Monocast 10 mg — Montelukast sodium 10 mg
Manufacturer: Beximco Pharmaceuticals Ltd.. Observed row: 0–0–0–1; after food marked.. Identification confidence: 0.98.
| Field / ক্ষেত্র | Patient-specific verified information / যাচাইকৃত তথ্য |
|---|---|
| 1. Generic ingredient(s) / জেনেরিক | Montelukast sodium 10 mg |
| 2. Brand / ব্র্যান্ড | Monocast |
| 3. Alternate Bangladesh brands / বিকল্প ব্র্যান্ড | Aeron 10 mg, Aircast 10 mg, Airmont 10 mg (same active ingredient). |
| 4. Therapeutic class / থেরাপিউটিক শ্রেণি | Leukotriene receptor antagonists |
| 5. Pharmacological class / ফার্মাকোলজিক শ্রেণি | CysLT₁ leukotriene receptor antagonist |
| 6. Primary purpose / প্রধান উদ্দেশ্য | Controller adjunct for asthma and allergic rhinitis; does not provide rapid relief of an asthma attack. |
| 7. Patient-specific reason / এই রোগীতে কেন | May have been prescribed for asthma/allergic-airway overlap or rhinitis, neither directly documented; not standard COPD monotherapy. |
| 8. Adverse effects / পার্শ্বপ্রতিক্রিয়া | Headache, abdominal discomfort; IMPORTANT boxed warning: sleep disturbances, anxiety, mood changes, suicidal thoughts or behaviour. |
| 9. Verified MedEx direct link / মেডএক্স সরাসরি | Open verified brand monograph |
| 10. Price, form, composition / দাম ও গঠন | Tablet; 10 mg; ৳17.50/tablet; ৳175/10-tablet strip; Montelukast sodium 10 mg. |
| 11. Mechanism / কার্যপ্রণালি | Blockade of cysteinyl leukotriene type-1 receptors reduces leukotriene-mediated airway inflammatory effects. |
| 12. Indications / ব্যবহার | Chronic asthma prevention, allergic rhinitis, exercise-induced bronchoconstriction prevention. |
| 13. Interactions and contraindications / মিথষ্ক্রিয়া ও নিষেধাজ্ঞা | Phenobarbital, rifampin and enzyme modulators may alter exposure; check comedications and mental-health symptoms. |
| 14. Precautions / সতর্কতা | Confirm asthma/rhinitis indication; if solely rhinitis, FDA recommends reserve for inadequate response/intolerance of alternatives; counsel neuropsychiatric warning. |
| 15. Dose & administration / ডোজ | Prescription: 10 mg nightly; adult label typically 10 mg once daily. |
| 16. Pregnancy & lactation / গর্ভাবস্থা ও স্তন্যদান | Clinical use only after individualized risk–benefit assessment; available data do not show a consistent major malformation signal; lactation consult reference. |
| 17. Other preparations & combinations / অন্যান্য ফর্ম | No fixed combination prescribed; inhaled controller therapy must be separately assessed if asthma exists. |
Clinical caution / সতর্কতা: Brand descriptions and typical indications are not evidence that the patient has every listed disease, nor a substitute for the prescribing doctor. Drug-price listings may change. MedEx source.
4. Lanso D 30 mg — Dexlansoprazole 30 mg
Manufacturer: Square Pharmaceuticals PLC. Observed row: 1–0–0–1 appears written (twice daily); BEFORE-food check appears marked; verify with original prescriber.. Identification confidence: 0.94.
| Field / ক্ষেত্র | Patient-specific verified information / যাচাইকৃত তথ্য |
|---|---|
| 1. Generic ingredient(s) / জেনেরিক | Dexlansoprazole 30 mg |
| 2. Brand / ব্র্যান্ড | Lanso D |
| 3. Alternate Bangladesh brands / বিকল্প ব্র্যান্ড | Aslan-D 30 mg, Canalia 30 mg, Delanix 30 mg (dexlansoprazole formulations; confirm precise formulation). |
| 4. Therapeutic class / থেরাপিউটিক শ্রেণি | Proton pump inhibitors |
| 5. Pharmacological class / ফার্মাকোলজিক শ্রেণি | Gastric H⁺/K⁺-ATPase inhibitor (dual delayed-release formulation) |
| 6. Primary purpose / প্রধান উদ্দেশ্য | Suppress gastric acid and relieve reflux/heartburn; promotes healing of erosive oesophagitis. |
| 7. Patient-specific reason / এই রোগীতে কেন | Co-prescribed reflux medications suggest possible GERD/dyspepsia, but no GI chief complaint is written. |
| 8. Adverse effects / পার্শ্বপ্রতিক্রিয়া | Headache, diarrhoea, abdominal pain; with prolonged use consider hypomagnesaemia, C. difficile risk and inappropriate continuation. |
| 9. Verified MedEx direct link / মেডএক্স সরাসরি | Open verified brand monograph |
| 10. Price, form, composition / দাম ও গঠন | Enteric-coated capsule; 30 mg; ৳10.00/capsule; ৳100/10-capsule strip; Dexlansoprazole 30 mg. |
| 11. Mechanism / কার্যপ্রণালি | Irreversibly inhibits proton pump in gastric parietal cells; dual delayed release causes two absorption peaks. |
| 12. Indications / ব্যবহার | Erosive oesophagitis treatment/maintenance, non-erosive symptomatic GERD. |
| 13. Interactions and contraindications / মিথষ্ক্রিয়া ও নিষেধাজ্ঞা | May alter absorption of pH-dependent agents; check rilpivirine and other contraindicated/problematic co-therapies. NOT a domperidone-containing product. |
| 14. Precautions / সতর্কতা | Important dose query: usual GERD 30 mg once daily; twice-daily notation would total 60 mg/day but is not the same as 60 mg once daily. Recheck indication and exact dose before use. |
| 15. Dose & administration / ডোজ | Prescription appears 1–0–0–1 (30 mg BID); manufacturer listing generally 30 mg ONCE daily for symptomatic non-erosive GERD. Do not silently “correct” prescription. |
| 16. Pregnancy & lactation / গর্ভাবস্থা ও স্তন্যদান | Use in pregnancy/lactation only when clinically justified; discuss safer established options. |
| 17. Other preparations & combinations / অন্যান্য ফর্ম | Brand suffix “D” does NOT mean this is combined with domperidone; ingredient verified as dexlansoprazole alone. Progavi is separate therapy. |
Clinical caution / সতর্কতা: Brand descriptions and typical indications are not evidence that the patient has every listed disease, nor a substitute for the prescribing doctor. Drug-price listings may change. MedEx source.
5. Efodio 10 mg — Domperidone maleate 10 mg
Manufacturer: Radiant Pharmaceuticals Ltd.. Observed row: 1–0–0–1 (20 mg/day) appears written; BEFORE-food check marked. User confirmed product identity.. Identification confidence: 1.00.
| Field / ক্ষেত্র | Patient-specific verified information / যাচাইকৃত তথ্য |
|---|---|
| 1. Generic ingredient(s) / জেনেরিক | Domperidone maleate 10 mg |
| 2. Brand / ব্র্যান্ড | Efodio |
| 3. Alternate Bangladesh brands / বিকল্প ব্র্যান্ড | Deflux 10 mg, Domiren 10 mg, Apuldon 10 mg (generic equivalents; same cardiovascular cautions). |
| 4. Therapeutic class / থেরাপিউটিক শ্রেণি | Prokinetics / antiemetics (MedEx-listed clinical use; exact display category may change) |
| 5. Pharmacological class / ফার্মাকোলজিক শ্রেণি | Peripheral dopamine D₂-receptor antagonist |
| 6. Primary purpose / প্রধান উদ্দেশ্য | Short-term relief of nausea/vomiting and delayed gastric emptying–related symptoms; not first-line maintenance for uncomplicated GERD. |
| 7. Patient-specific reason / এই রোগীতে কেন | Potential upper-GI symptoms are inferred from other acid-reflux medications, not directly documented. |
| 8. Adverse effects / পার্শ্বপ্রতিক্রিয়া | QT prolongation, ventricular arrhythmia/sudden cardiac death (risk higher in patients >60 or with cardiac disease), dry mouth, hyperprolactinaemia. |
| 9. Verified MedEx direct link / মেডএক্স সরাসরি | Open verified brand monograph |
| 10. Price, form, composition / দাম ও গঠন | Tablet; 10 mg; ৳4.50/tablet; ৳45/10-tablet strip; Domperidone maleate 10 mg. |
| 11. Mechanism / কার্যপ্রণালি | Peripheral D₂ blockade increases upper gastrointestinal motility and blocks dopaminergic antiemetic pathways. |
| 12. Indications / ব্যবহার | Nausea and vomiting; certain dyspeptic symptoms per local monograph. European regulators restrict licensed use to nausea/vomiting. |
| 13. Interactions and contraindications / মিথষ্ক্রিয়া ও নিষেধাজ্ঞা | Contraindicated with QT-prolonging agents and strong CYP3A4 inhibitors (e.g., clarithromycin, azole antifungals); electrolyte disturbances compound risk. |
| 14. Precautions / সতর্কতা | HIGHEST medication-safety concern: age ~60, “?IHD” and undocumented baseline ECG/QTc/electrolytes. Confirm cardiac history and appropriateness urgently before dispensing/continuing; avoid if underlying cardiac disease/QT prolongation. |
| 15. Dose & administration / ডোজ | Prescription appears 10 mg twice daily. EMA recommends adults 10 mg up to 3 times/day, maximum 30 mg/day, generally no longer than 1 week for nausea/vomiting; duration not legible here. |
| 16. Pregnancy & lactation / গর্ভাবস্থা ও স্তন্যদান | Generally avoid unless benefits outweigh risks; small amounts in milk; discuss infant/cardiac risks. |
| 17. Other preparations & combinations / অন্যান্য ফর্ম | Not part of Lanso D 30 mg; this is a separate domperidone medicine. Review potential additive proarrhythmia with other drugs. |
Clinical caution / সতর্কতা: Brand descriptions and typical indications are not evidence that the patient has every listed disease, nor a substitute for the prescribing doctor. Drug-price listings may change. MedEx source.
6. Progavi (500+213+325) mg / 10 mL — Sodium alginate 500 mg + sodium bicarbonate 213 mg + calcium carbonate 325 mg per 10 mL
Manufacturer: Beximco Pharmaceuticals Ltd.. Observed row: Handwriting appears “2 teaspoons” morning and at night, after food; hand notation is indistinct—mL MUST be confirmed.. Identification confidence: 1.00.
| Field / ক্ষেত্র | Patient-specific verified information / যাচাইকৃত তথ্য |
|---|---|
| 1. Generic ingredient(s) / জেনেরিক | Sodium alginate 500 mg + sodium bicarbonate 213 mg + calcium carbonate 325 mg per 10 mL |
| 2. Brand / ব্র্যান্ড | Progavi |
| 3. Alternate Bangladesh brands / বিকল্প ব্র্যান্ড | Abicon Max and Algicid DX (same 500+213+325 mg/10 mL); other “Plus” brands have DIFFERENT strengths. |
| 4. Therapeutic class / থেরাপিউটিক শ্রেণি | Antacids and anti-reflux preparations |
| 5. Pharmacological class / ফার্মাকোলজিক শ্রেণি | Alginate raft-forming agent + bicarbonate/carbonate antacids |
| 6. Primary purpose / প্রধান উদ্দেশ্য | Rapid heartburn/reflux relief, physical barrier to oesophageal reflux. |
| 7. Patient-specific reason / এই রোগীতে কেন | Suggests symptomatic reflux, yet heartburn/regurgitation are not recorded as complaints. |
| 8. Adverse effects / পার্শ্বপ্রতিক্রিয়া | Bloating, belching; excessive calcium may lead to hypercalcaemia/constipation; sodium load matters in salt-restricted patients. |
| 9. Verified MedEx direct link / মেডএক্স সরাসরি | Open verified brand monograph |
| 10. Price, form, composition / দাম ও গঠন | Oral suspension (patient called it syrup); (500+213+325) mg / 10 mL; ৳300/200-mL bottle; ৳15 per 10-mL sachet; Sodium alginate 500 mg + sodium bicarbonate 213 mg + calcium carbonate 325 mg per 10 mL. |
| 11. Mechanism / কার্যপ্রণালি | Alginate reacts with gastric acid to form a floating gel raft; bicarbonate and calcium carbonate neutralise acidity. |
| 12. Indications / ব্যবহার | Gastric reflux, heartburn, postprandial dyspepsia. |
| 13. Interactions and contraindications / মিথষ্ক্রিয়া ও নিষেধাজ্ঞা | Separate from oral medicines by ~2 hours where product/interacting-medication guidance indicates; calcium carbonate alters absorption of certain drugs (e.g., tetracyclines, levothyroxine, iron). |
| 14. Precautions / সতর্কতা | Confirm teaspoon-to-mL translation with measured device; assess sodium burden if heart failure, oedema, severe kidney disease, or salt restriction. No confirmed HF diagnosis here. |
| 15. Dose & administration / ডোজ | Source guidance: adults usually 10–20 mL after meals and bedtime, up to four times/day. Prescription wording is insufficiently clear to establish actual mL or frequency. |
| 16. Pregnancy & lactation / গর্ভাবস্থা ও স্তন্যদান | Alginate antacid formulations are commonly used in pregnancy when indicated; sodium restrictions may still apply; lactation generally low concern. |
| 17. Other preparations & combinations / অন্যান্য ফর্ম | Three actives in this ONE liquid; not an antibiotic, not an antitussive. |
Clinical caution / সতর্কতা: Brand descriptions and typical indications are not evidence that the patient has every listed disease, nor a substitute for the prescribing doctor. Drug-price listings may change. MedEx source.
7. Abdolax 10 mg — Sodium picosulfate 10 mg
Manufacturer: Incepta Pharmaceuticals Ltd.. Observed row: 0–0–0–1 at night; adjacent handwritten condition cannot be read reliably; may be PRN rather than scheduled.. Identification confidence: 0.96.
| Field / ক্ষেত্র | Patient-specific verified information / যাচাইকৃত তথ্য |
|---|---|
| 1. Generic ingredient(s) / জেনেরিক | Sodium picosulfate 10 mg |
| 2. Brand / ব্র্যান্ড | Abdolax |
| 3. Alternate Bangladesh brands / বিকল্প ব্র্যান্ড | Befree 10 mg, Clenpic 10 mg, Easylet 10 mg (same generic, strength; check availability). |
| 4. Therapeutic class / থেরাপিউটিক শ্রেণি | Stimulant laxatives |
| 5. Pharmacological class / ফার্মাকোলজিক শ্রেণি | Locally activated stimulant laxative (colonic prodrug) |
| 6. Primary purpose / প্রধান উদ্দেশ্য | Short-term relief of constipation and facilitating bowel evacuation. |
| 7. Patient-specific reason / এই রোগীতে কেন | Constipation is plausible due to the drug, but it is NOT explicitly written in C/C. |
| 8. Adverse effects / পার্শ্বপ্রতিক্রিয়া | Abdominal cramps, diarrhoea, dehydration, dizziness, hypokalaemia with excessive use. |
| 9. Verified MedEx direct link / মেডএক্স সরাসরি | Open verified brand monograph |
| 10. Price, form, composition / দাম ও গঠন | Tablet; 10 mg; ৳10.00/tablet; ৳100/10-tablet strip; Sodium picosulfate 10 mg. |
| 11. Mechanism / কার্যপ্রণালি | Colonic bacteria activate drug, stimulating peristalsis and intraluminal water/electrolyte accumulation. |
| 12. Indications / ব্যবহার | Constipation; bowel preparation in specific settings. |
| 13. Interactions and contraindications / মিথষ্ক্রিয়া ও নিষেধাজ্ঞা | Excessive use with diuretics or corticosteroids raises electrolyte imbalance risk; other laxatives may worsen dehydration. |
| 14. Precautions / সতর্কতা | Exclude obstruction, severe acute abdomen, marked dehydration; avoid chronic unsupervised use; check stool habits/medications and electrolyte context. |
| 15. Dose & administration / ডোজ | Prescription appears 10 mg at bedtime, possibly if needed; verify the handwritten phrase. Standard adult label range 5–10 mg at night. |
| 16. Pregnancy & lactation / গর্ভাবস্থা ও স্তন্যদান | Use cautiously and only after non-drug measures; lactation generally limited systemic absorption but individualized advice needed. |
| 17. Other preparations & combinations / অন্যান্য ফর্ম | Not a fibre replacement; review bowel regimen, medications and clinical cause rather than escalating laxatives automatically. |
Clinical caution / সতর্কতা: Brand descriptions and typical indications are not evidence that the patient has every listed disease, nor a substitute for the prescribing doctor. Drug-price listings may change. MedEx source.
09. Bangladesh Drug Options — Matched-Generic Price Comparison / একই জেনেরিকের বিকল্প ও দাম
| Original | One verified same-ingredient example | Listed price | Important distinction |
|---|---|---|---|
| Abecab 5/20 (৳12) | Bazoka 5/20 | ৳10/tablet | Same ingredient and strength; brands not interchangeable without pharmacist review |
| Brezofil 200 (৳8) | Docofin 200 | ৳7.50/tablet | Doxophylline; check immediate-release vs SR |
| Monocast 10 (৳17.50) | Aeron 10 | ৳17.50/tablet | Montelukast; same FDA neuropsychiatric warning |
| Lanso D 30 (৳10) | Aslan-D 30 | ৳10/capsule | Dexlansoprazole; NOT domperidone |
| Efodio 10 (৳4.50) | Deflux 10 | ৳4/tablet | Domperidone; same QT caution |
| Progavi 200 mL (৳300) | Algicid DX 200 mL | ৳300/bottle | Exact 500/213/325 mg/10 mL; do not substitute “Plus” strengths blindly |
| Abdolax 10 (৳10) | Easylet 10 | ৳7/tablet | Sodium picosulfate; confirm if PRN |
Prices were cross-checked on MedEx listings (accessed 03 November 2026) and are listed retail reference prices, not a local pharmacy quote. Comparison is for education, not a switching recommendation. Generic directories: Abecab, Brezofil, Monocast, Lanso D, Efodio, Progavi, Abdolax.
10. Highest-Priority Medication Safety Audit / জরুরি ওষুধ-নিরাপত্তা যাচাই
Priority 1 — Domperidone in cardiac-risk patient: Efodio 10 mg appears twice daily. Patient is ~60 and ?IHD is handwritten; neither ECG/QTc nor serum K/Mg appears. EMA guidance notes higher arrhythmic risk in patients older than 60, daily doses >30 mg, interacting QT/CYP3A4 drugs, and those with underlying cardiac disease. The proposed 20 mg/day does not remove the underlying contraindication where cardiac disease/QT impairment exists. This calls for prompt review of necessity, indication, ECG/QTc, electrolytes, drug list, and intended very short course. / সম্ভাব্য হৃদ্রোগে ডমপেরিডন দেওয়ার আগে QT ও ওষুধের মিথস্ক্রিয়া যাচাই জরুরি। Confidence: 0.98.
Priority 2 — Lanso D frequency: The brand is dexlansoprazole 30 mg, not lansoprazole+domperidone. Its line resembles one morning plus one night (=60 mg/day as two 30-mg doses). Standard non-erosive GERD label is 30 mg once daily; clarify whether this twice-daily pattern is genuine, deliberate and time limited. “Before food” is written, although dexlansoprazole capsules can usually be taken without regard to meals. / ভুল করে ডমপেরিডনযুক্ত কম্বিনেশন ধরবেন না। Confidence: 0.96.
Priority 3 — COPD therapy alignment: Doxophylline plus montelukast does not by itself establish comprehensive contemporary COPD management. GOLD 2026 prioritizes inhaled bronchodilation tailored to symptoms/exacerbations, inhaler technique, risk reduction and vaccinations; verify whether the patient is already using LAMA/LABA inhalers, and whether there is asthma overlap before labeling the regimen deficient. / COPD-এর স্ট্যান্ডার্ড ইনহেলার নেওয়া হচ্ছে কি না জেনে মূল্যায়ন করুন। Confidence: 0.94.
Priority 4 — Two GI acid-relief agents and GI prokinetic: Dexlansoprazole + alginate may be complementary if symptomatic reflux persists, but domperidone has narrower benefit and greater cardiac concern. Define symptom and intended duration; avoid indefinite empirical continuation. Confidence: 0.93.
Priority 5 — Sodium, fluid and electrolytes: Progavi contains sodium bicarbonate and sodium alginate, relevant to a sodium-restricted patient; Abdolax-related diarrhoea may disturb K/Mg and potentiate arrhythmia risk. No confirmed heart failure, CKD, or electrolyte abnormality is documented. Confidence: 0.91.
Priority 6 — Montelukast warning: Ask about nightmares, insomnia, depression, mood changes and suicidal ideas; FDA boxed warning remains pertinent in asthma/rhinitis treatment, especially if the clinical indication is unclear. Confidence: 0.99.
11. Fourteen Advanced Clinical Assessment Parameters / অতিরিক্ত ১৪টি ক্লিনিক্যাল পরামিতি
1. Clinical Decision-Making Algorithm — ধাপে ধাপে চিকিৎসা-সিদ্ধান্ত
Patient-specific assessment / রোগীভিত্তিক পর্যালোচনা: History (current symptoms, tobacco/biomass, prior ECHO/CAD, exacerbations) → vitals and 12-lead ECG → reconcile every medication and exact dose → BMP/K/Mg/eGFR → spirometry after bronchodilator when stable → coronary work-up if compatible symptoms → review inhaled maintenance therapy, reflux and bowel needs → follow-up BP, symptom burden and treatment tolerance.
সহজ বাংলা: ইতিহাস–ECG–ইলেকট্রোলাইট–স্পাইরোমেট্রি–ওষুধ যাচাই–ফলোআপ।
Confidence / নির্ভরযোগ্যতা: 0.97.
2. Diagnostic Evidence & Uncertainty — প্রমাণ ও অনিশ্চয়তা
Patient-specific assessment / রোগীভিত্তিক পর্যালোচনা: Do not convert a queried IHD note to confirmed CAD, a quoted EF to an actual report, a medication list to symptom documentation, or a clear lung exam to proof of absent COPD.
সহজ বাংলা: প্রেসক্রিপশনের আন্দাজকে প্রমাণিত রোগ বলা যাবে না।
Confidence / নির্ভরযোগ্যতা: 0.99.
3. Prescription Safety Audit — ওষুধের নিরাপত্তা
Patient-specific assessment / রোগীভিত্তিক পর্যালোচনা: Top concerns: domperidone QT risk; verify 30-mg BID PPI; stimulant laxative frequency; doxophylline in potential cardiac disease; montelukast mental-health warning; dose/volume ambiguity in Progavi.
সহজ বাংলা: ইফোডিও, ল্যানসো ডি, অ্যাবডোল্যাক্স, প্রোগ্যাভি বিশেষ যাচাই।
Confidence / নির্ভরযোগ্যতা: 0.98.
4. Red Flags & Emergency Referral — বিপদচিহ্ন
Patient-specific assessment / রোগীভিত্তিক পর্যালোচনা: Acute chest pressure radiating to jaw/arm, severe breathlessness, syncope, palpitations with collapse, new cyanosis, confusion or oxygen desaturation → emergency assessment. Haematemesis, black tarry stool, severe abdominal pain/obstruction also urgent.
সহজ বাংলা: বুকে চাপ, অজ্ঞান, তীব্র শ্বাসকষ্ট, কালো পায়খানা হলে জরুরি চিকিৎসা।
Confidence / নির্ভরযোগ্যতা: 0.99.
5. Evidence-Based Treatment Comparison — প্রমাণভিত্তিক চিকিৎসা
Patient-specific assessment / রোগীভিত্তিক পর্যালোচনা: For HTN, guideline-based BP confirmation and ARB/CCB is coherent. For COPD, inhaled LABA/LAMA-based symptom/exacerbation-specific care has stronger guideline support than relying only on oral xanthines and montelukast. For GERD, time-limited PPI with lifestyle/alginate is reasonable if symptomatic; prokinetic needs clear indication and cardiac check.
সহজ বাংলা: রোগভিত্তিক মানসম্মত চিকিৎসার সঙ্গে তুলনা; স্বয়ংক্রিয় ওষুধ পরিবর্তন নয়।
Confidence / নির্ভরযোগ্যতা: 0.94.
6. Follow-up & Outcomes — ফলোআপ ও ফলাফল
Patient-specific assessment / রোগীভিত্তিক পর্যালোচনা: Repeat BP with home log (morning/evening over several days), pulse, symptoms and adverse effects; check creatinine/K 2–4 weeks after ARB initiation or titration; assess COPD symptoms (CAT/mMRC) and exacerbations; review reflux response, bowel pattern, and whether domperidone was stopped on schedule.
সহজ বাংলা: BP, কিডনি, শ্বাসের অবস্থা, পার্শ্বপ্রতিক্রিয়ার ফলোআপ।
Confidence / নির্ভরযোগ্যতা: 0.96.
7. Investigation Interpretation — পরীক্ষার অর্থ
Patient-specific assessment / রোগীভিত্তিক পর্যালোচনা: A historical EF 50–55% is not a current EF report; no echo images/date. COPD severity cannot be assigned without spirometry; BP 130/90 on one day is not reliable longitudinal control. ECG cannot be inferred from a printed ECG field.
সহজ বাংলা: EF, COPD গ্রেড, ECG—সবই রিপোর্ট ছাড়া নিশ্চিত নয়।
Confidence / নির্ভরযোগ্যতা: 0.98.
8. Patient Education (Bangla) — রোগীকে সহজ শিক্ষা
Patient-specific assessment / রোগীভিত্তিক পর্যালোচনা: শুধু ওষুধের নাম দেখে রোগ নিশ্চিত হয় না। হৃদ্রোগের সন্দেহ থাকলে ইফোডিও নিরাপদ কি না ডাক্তারকে জিজ্ঞেস করুন। নিজে থেকে ওষুধ বন্ধ/শুরু করবেন না। ওষুধের চামচের বদলে মাপার সিরিঞ্জ/কাপ ব্যবহার করুন।
সহজ বাংলা: শ্বাসকষ্ট, বুকে ব্যথা বা অজ্ঞান হলে দেরি করবেন না।
Confidence / নির্ভরযোগ্যতা: 0.98.
9. Guideline Update & Evidence Quality — গাইডলাইন ও প্রমাণ
Patient-specific assessment / রোগীভিত্তিক পর্যালোচনা: GOLD 2026 (COPD); AHA/ACC 2025 BP; ESC 2024 coronary syndromes; ACG 2022 reflux; EMA domperidone and FDA 2020 montelukast safety notices. Drug brands/prices verified on MedEx, which is not a substitute for guideline recommendations.
সহজ বাংলা: ব্র্যান্ড তথ্য MedEx, চিকিৎসা পরিকল্পনা আন্তর্জাতিক গাইডলাইনে যাচাই।
Confidence / নির্ভরযোগ্যতা: 0.99.
10. Medical SEO & Article Transparency — মেডিক্যাল SEO ও স্বচ্ছতা
Patient-specific assessment / রোগীভিত্তিক পর্যালোচনা: Suggested slug: copd-htn-possible-ihd-seven-drug-prescription-review; SEO description: Adult male with COPD and HTN, possible IHD and seven medicines including Efodio and Progavi—bilingual medication-safety assessment. Exclude patient name/contact and do not reproduce unredacted photo.
সহজ বাংলা: রোগীর পরিচয় গোপন রেখে প্রকাশ।
Confidence / নির্ভরযোগ্যতা: 0.99.
11. Guideline-Based Additional Drug Assessment — সম্ভাব্য অতিরিক্ত ওষুধ
Patient-specific assessment / রোগীভিত্তিক পর্যালোচনা: Do NOT automatically add aspirin/statins: first establish actual CAD and lipid/bleeding history. Do NOT automatically add inhaled corticosteroid to COPD: assess exacerbations, eosinophils and asthma. If COPD symptoms persist, clinician may consider inhaled long-acting bronchodilator(s) per GOLD.
সহজ বাংলা: বিনা প্রমাণে অ্যাসপিরিন, স্ট্যাটিন, স্টেরয়েড বা ইনহেলার শুরু নয়।
Confidence / নির্ভরযোগ্যতা: 0.94.
12. Additional Investigations for Confirmation — আরও পরীক্ষা
Patient-specific assessment / রোগীভিত্তিক পর্যালোচনা: 12-lead ECG/QTc; CBC; K/Mg/Na; creatinine/eGFR; glucose or HbA1c; lipid panel; post-BD spirometry; verify prior ECHO report; repeat ECHO if indicated by symptoms; oxygen saturation; chest radiograph if indicated; CAD functional/anatomic testing only after symptom/risk assessment.
সহজ বাংলা: সবার জন্য সব পরীক্ষা নয়—উপসর্গ অনুযায়ী বাছাই।
Confidence / নির্ভরযোগ্যতা: 0.97.
13. Polypharmacy & Unnecessary-Drug Assessment — বহু ওষুধের যৌক্তিকতা
Patient-specific assessment / রোগীভিত্তিক পর্যালোচনা: Seven products, including three upper-GI-directed drugs. Risk is not the count alone: unexplained indications/durations, drug–disease interaction with possible IHD, and potential long-term PPI/prokinetic use matter. Assess actual current regimen and OTC drugs.
সহজ বাংলা: অপ্রয়োজনীয় ওষুধ কি আছে—উপসর্গ ও মেয়াদ দেখে বিচার।
Confidence / নির্ভরযোগ্যতা: 0.96.
14. Patient Counselling & Administration — সেবনবিধি ও কাউন্সেলিং
Patient-specific assessment / রোগীভিত্তিক পর্যালোচনা: Confirm whether Progavi “two teaspoons” is 10 mL and whether twice daily or more; separate from interacting medications if required. Verify Abdolax nightly versus PRN, Lanso D once/twice daily, and total duration of all seven. Check inhaler technique, smoking cessation and exposure avoidance.
সহজ বাংলা: চামচের পরিমাপ ও ওষুধের মেয়াদ লিখে পরিষ্কার করে নিন।
Confidence / নির্ভরযোগ্যতা: 0.98.
12. Prescription Demo — Clinical Documentation Only / ডেমো প্রেসক্রিপশন নোট
NOT a new treatment order — কেবল নথিবদ্ধকরণের ডেমো: Male ~60, date 17 July 2026; histories COPD and HTN, ?IHD (reported EF 50–55%). BP 130/90; pulse ~86; lungs clear. No diagnostic studies attached. Seven listed drugs as detailed above. Suggested chart wording: “Review QTc/electrolytes and domperidone contraindications; confirm PPI and liquid medication directions; obtain COPD spirometry and reconcile inhaler history; assess CAD symptoms before labeling confirmed IHD.” / এটি নতুন প্রেসক্রিপশন নয়।
13. Referral / কোন বিভাগে রেফার করবেন?
Cardiology: Review ?IHD, ECG/QTc, symptoms, medication cardiac safety; urgent if chest pain/syncope. Pulmonology / Respiratory Medicine: spirometry and inhaled regimen assessment for COPD and possible asthma coexistence. Internal Medicine / Gastroenterology: if persistent reflux, dysphagia or drug-risk complexity. Pharmacist: urgent seven-drug reconciliation and exact dosage transcription. / কার্ডিওলজি ও বক্ষব্যাধি বিশেষজ্ঞের মূল্যায়ন গুরুত্বপূর্ণ। Confidence: 0.98.
14. Overview / Summary — সারসংক্ষেপ
English: This July 2026 prescription belongs to a roughly 60-year-old man with documented COPD and HTN and a questioned IHD entry (EF appears 50–55%). There are seven medicines. Efodio 10 mg is domperidone and Progavi is sodium alginate/sodium bicarbonate/calcium carbonate suspension, verified from MedEx. The highest patient-specific issue is domperidone’s potentially serious arrhythmia risk in possible cardiac disease; the Lanso D dosage and indistinct Progavi/Abdolax directions also require verification. No confirmed GERD, constipation, new CAD, heart failure, or COPD severity can be established from the photograph alone. Confidence: 0.96 for summary accuracy.
বাংলা সারাংশ: প্রেসক্রিপশনে COPD ও উচ্চ রক্তচাপ লেখা আছে; IHD-এর আগে প্রশ্নবোধক চিহ্ন আছে, তাই নিশ্চিত হৃদ্রোগ বলা যাবে না। EF সম্ভবত ৫০–৫৫% লেখা, কিন্তু ECHO রিপোর্ট নেই। ৫ নম্বর Efodio 10 mg = Domperidone এবং ৬ নম্বর Progavi = এসিড রিফ্লাক্সের জন্য Alginate/Antacid suspension। হৃদ্রোগের সম্ভাবনা থাকায় ডমপেরিডনের QT ঝুঁকি বিশেষভাবে মূল্যায়ন দরকার। Lanso D-এর মাত্রা এবং সিরাপের কত মিলিলিটার/কতবার নেওয়া হবে তা প্রেসক্রাইবার থেকে নিশ্চিত করতে হবে।
15. Actionable Plan / Steps — করণীয়
| Priority | Clinical action / করণীয় | What not to assume |
|---|---|---|
| Today / same-day review when clinically relevant | Check why domperidone prescribed, full cardiac history, current drugs (QT/CYP3A4), symptoms, ECG/QTc and electrolytes as appropriate. | Do not assume a 20-mg/day dose is automatically safe with cardiac disease. |
| Before next dose from unclear handwriting | Verify Lanso D 30 mg frequency and duration; Progavi volume in mL and frequency; Abdolax scheduled vs as-needed; check expiry/course. | Do not silently convert handwriting to binding patient instructions. |
| Next routine clinical review | Assess COPD with stable-state post-BD spirometry, symptom/exacerbation history, oxygen saturation and existing inhaler list. | Do not conclude COPD is ruled out because lungs were clear. |
| Cardiovascular risk | Recheck BP log, renal function/K+, lipid panel, glucose; assess chest symptoms and retrieve dated ECHO/ECG before labeling IHD. | Do not convert ?IHD into confirmed coronary disease. |
| Patient counselling | Discuss triggers, tobacco/biomass cessation, reflux warning signs, bowel habits, montelukast mood/sleep changes, urgent red flags. | Do not self-start or stop cardiovascular drugs. |
16. Final Clinical Judgment — চূড়ান্ত ক্লিনিক্যাল রায়
Conclusion: The physician clearly treated hypertension and airway disease, but the photograph contains insufficient evidence to establish all diagnoses or to assess the full appropriateness of the regimen. Efodio–cardiac safety is the most consequential concern, followed by uncertain Lanso D dosing, incomplete COPD guideline documentation and ambiguous liquid/laxative instructions. This is a retrospective educational clinical audit rather than a diagnosis or treatment order. Overall reliability of the documented-data audit: 0.94; uncertainty in unrecorded clinical symptoms is substantial.
চূড়ান্ত মন্তব্য: প্রেসক্রিপশনের সাতটি ওষুধের জেনেরিক নিশ্চিত করা হয়েছে। ৫ নম্বর Efodio ও ৬ নম্বর Progavi ব্যবহারকারীর দেওয়া নাম অনুযায়ী পৃথকভাবে যাচাই করা হয়েছে। নথিতে নেই এমন উপসর্গ/রোগ নিশ্চিত ধরে নেওয়া হয়নি। কোনো ওষুধ বাদ দেওয়া বা নতুন ওষুধ শুরু করার সিদ্ধান্ত রোগীকে দেখে চিকিৎসক নেবেন।
17. Verified References / যাচাইকৃত তথ্যসূত্র
Textbook context (no inaccessible page numbers claimed): Harrison’s Principles of Internal Medicine, 22nd ed. (2025): systemic hypertension, COPD and chronic ischaemic heart disease chapters; Davidson’s Principles and Practice of Medicine, 25th ed. (2026): cardiovascular and respiratory disease chapters; Goodman & Gilman’s The Pharmacological Basis of Therapeutics: antihypertensives, airway drugs, GI pharmacotherapy chapters. Chapter numbering and page numbers should be checked against the user’s owned edition before printing.
Current guideline and DOI sources:
[1] Website category tally (checked 03 Nov 2026).
[2] Cardiology archive (Case 50 most recent).
[4] AHA/ACC 2025 hypertension guideline; DOI: 10.1161/CIR.0000000000001356.
[5] ESC 2024 chronic coronary syndromes; DOI: 10.1093/eurheartj/ehae177.
[6] ACG 2022 GERD guideline; DOI: 10.14309/ajg.0000000000001538.
[7] EMA domperidone restrictions (2014; current safety reference).
[8] US FDA montelukast boxed warning (2020).
MedEx primary brand monographs / বাংলাদেশের ব্র্যান্ড যাচাই:
[1] Abecab — Amlodipine besilate 5 mg + olmesartan medoxomil 20 mg. Verified 03 November 2026; price subject to change.
[2] Brezofil — Doxophylline 200 mg. Verified 03 November 2026; price subject to change.
[3] Monocast — Montelukast sodium 10 mg. Verified 03 November 2026; price subject to change.
[4] Lanso D — Dexlansoprazole 30 mg. Verified 03 November 2026; price subject to change.
[5] Efodio — Domperidone maleate 10 mg. Verified 03 November 2026; price subject to change.
[6] Progavi — Sodium alginate 500 mg + sodium bicarbonate 213 mg + calcium carbonate 325 mg per 10 mL. Verified 03 November 2026; price subject to change.
[7] Abdolax — Sodium picosulfate 10 mg. Verified 03 November 2026; price subject to change.
Medical disclaimer: This article is a de-identified educational critique of a photographed prescription, dated 17 July 2026. Reviewer did not independently examine the patient, review ECG/ECHO/spirometry, or confirm a dispensing history. Any redacted or uncertain readings must be checked before clinical use. | রোগীর গোপনীয়তা রক্ষা করা হয়েছে; এটি সরাসরি রোগী পরীক্ষা বা নতুন চিকিৎসার বিকল্প নয়।